Search Results - "Boffito, M."

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.

Authors: Boyd, MA Boffito, M Castagna, A et al.

Source: HIV Medicine. Mar2019 Supplement S1, Vol. 20, p3-11. 9p.

In vitro and patient studies with platelets to explore off‐target cardiovascular effects of integrase inhibitors.

Authors: Keniyopoullos, R. Khawaja, A. A. Boffito, M. et al.

Source: HIV Medicine. Feb2025, Vol. 26 Issue 2, p285-294. 10p.

Screening for HIV-related neurocognitive impairment in clinical practice: Challenges and opportunities.

Authors: Barber, T.J. Bradshaw, D. Hughes, D. et al.

Source: AIDS Care. Feb2014, Vol. 26 Issue 2, p160-168. 9p.

Subjects: Diagnosis of central nervous system diseases, Cognition disorders diagnosis, Antiviral agents, HIV infection complications, Health services administration, Neuropsychological tests, Disease prevalence

Geographic Terms: United Kingdom

Therapeutic nanoparticles from novel multiblock engineered polyesterurethanes.

Authors: Mattu, C. Boffito, M. Sartori, S. et al.

Source: Journal of Nanoparticle Research. Dec2012, Vol. 14 Issue 12, p1-13. 13p.

Unexpected drug interactions and adverse events with antiretroviral drugs [corrected] [published errata appear in NURS STAND 2009 Jun 3-9;23(39):33, and 10-16;23(40):33].

Authors: Moyle G Boffito M

Source: Lancet. 7/3/2004, Vol. 364 Issue 9428, p8-10. 3p.

Étude RETRO : utilisation du raltégravir 1200 mg une fois par jour en vie réelle.

Authors: Mariot, P. Boffito, M. Ustianowski, A. et al.

Source: Medecine & Maladies Infectieuses. 2020 Supplement, Vol. 50 Issue 6, pS192-S192. 1p.

British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011.

Authors: Asboe, D Aitken, C Boffito, M et al.

Source: HIV Medicine. Jan2012, Vol. 13 Issue 1, p1-44. 44p. 3 Charts.

In Vitro Models of Bacterial Biofilms: Innovative Tools to Improve Understanding and Treatment of Infections.

Authors: Crivello, G. Fracchia, L. Ciardelli, G. et al.

Source: Nanomaterials (2079-4991). Mar2023, Vol. 13 Issue 5, p904. 21p.

Subjects: Biofilms, Drug resistance in bacteria, Bacterial diseases, Human body, Medical care, Antibiotics

Abstract: P714 LOW-DOSE RITONAVIR INDUCED DRASTIC CHANGES IN CD36 AND ADIPOPHILIN EXPRESSIONS IN PERIPHERAL BLOOD MONOCYTIC CELLS FROM HEALTHY VOLUNTEERS

Authors: Collot-Teixeira, S Boffito, M de Lorenzo, F et al.

Source: Atherosclerosis (Supplements). Jun2009, Vol. 10 Issue 2, pe900-e900. 1p.

EFFECT OF STATINS ON THE REGULATION AND EXPRESSION OF CANDIDATE GENE (CD 36) IN ATHEROSCLEROSIS

Authors: de Lorenzo, F. Boffito, M. Feher, M. et al.

Source: Atherosclerosis (Supplements). May2008, Vol. 9 Issue 1, p41-41. 1p.

ATHEROSCLEROSIS RISK FACTORS IN PLASMA (HDL, TRIGLYCERIDES) AND CIRCULATING MONOCYTES (CD36) ARE SIGNIFICANTLY ALTERED BY LOW-DOSE RITONAVIR IN HEALTHY VOLUNTEERS

Authors: Collot-Teixeira, S. Boffito, M. de lorenzo, F. et al.

Source: Atherosclerosis (Supplements). May2008, Vol. 9 Issue 1, p39-39. 1p.

Respiratory symptoms and chronic bronchitis in people with and without HIV infection.

Authors: Sabin, CA Kunisaki, KM Bagkeris, E et al.

Source: HIV Medicine. Jan2021, Vol. 22 Issue 1, p11-21. 11p.

Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross‐sectional analysis.

Authors: Savinelli, S De Francesco, D Feeney, ER et al.

Source: HIV Medicine. Aug2020, Vol. 21 Issue 7, p441-452. 12p.

CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.

Authors: Barber, T. J. Imaz, A. Boffito, M. et al.

Source: Journal of NeuroVirology. Feb2018, Vol. 24 Issue 1, p98-105. 8p.

Level of agreement between frequently used cardiovascular risk calculators in people living with HIV.

Authors: Dhillon, S Sabin, CA Alagaratnam, J et al.

Source: HIV Medicine. May2019, Vol. 20 Issue 5, p347-352. 6p.

Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells.

Authors: Mattu, C. Pabari, R.M. Boffito, M. et al.

Source: European Journal of Pharmaceutics & Biopharmaceutics. Nov2013, Vol. 85 Issue 3 Part A, p463-472. 10p.

InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.

Authors: Wang, X. Nwokolo, N. Korologou‐Linden, R. et al.

Source: HIV Medicine. Jan2018, Vol. 19 Issue 1, p1-6. 6p.

Out of focus: tailoring the cascade of care to the needs of women living with HIV.

Authors: Geretti, AM Loutfy, M D'Arminio Monforte, A et al.

Source: HIV Medicine. Sep2017 Supplement S2, Vol. 18, p3-17. 15p.

Associations between cognitive impairment and patient-reported measures of physical/mental functioning in older people living with HIV.

Authors: Underwood, J De Francesco, D Post, FA et al.

Source: HIV Medicine. May2017, Vol. 18 Issue 5, p363-369. 7p.

The role of tenofovir alafenamide in future HIV management.

Authors: Antela, A. Aguiar, C. Compston, J. et al.

Source: HIV Medicine. 2016 Supplement, Vol. 17, p4-16. 13p.